BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy, infigratinib in children with achondroplasia will be featured in an oral presentation at the Endocrine Society (ENDO) 2023 Annual Conference, taking place in Chicago, Illinois on June 15 – 18, 2023.
At ENDO 2023, BridgeBio will also present additional data from its achondroplasia program and nonclinical results from studies in hypochondroplasia. Furthermore, the Company will share updates from its autosomal dominant hypocalcemia type 1 (ADH1) program, including 18 month data from its ongoing Phase 2 study of encaleret in ADH1 and its sponsored hypoparathyroidism genetic testing program.
To access the oral presentation and poster materials following the Company’s participation at ENDO 2023, please visit https://investor.bridgebiodev.wpengine.com/presentations.
Achondroplasia oral presentation and poster details:
Oral infigratinib treatment is well tolerated and
significantly increases height velocity in children with
achondroplasia: Month 6 results from the PROPEL 2 dose-finding
study
Presenter: Ravi Savarirayan, M.D., Ph.D.,
clinical geneticist and group leader of molecular therapies
research at the Murdoch Children’s Research Institute in
Australia, the lead investigator for PROPEL2
Oral presentation date & time: Saturday,
June 17 at 4:00 pm CT
Location: W-184BC, McCormick Place
Session title: Late Breaking II
Session number: OR27-03
Low-dose infigratinib, an oral selective fibroblast growth
factor receptor (FGFR) tyrosine kinase inhibitor, demonstrates
activity in murine models of achondroplasia and
hypochondroplasia
Presenter: Elena Muslimova, Ph.D., medical
director of skeletal dysplasias program at BridgeBio
Oral presentation date & time: Saturday,
June 17 at 4:30 pm CT
Location: W-178B, McCormick Place
Session title: Update on pediatric growth
disorders
Session number: OR21-05
PROPEL, PROPEL 2 and PROPEL OLE studies of infigratinib in
children with achondroplasia: design and status of 3 ongoing
trials
Poster presentation date & time: Thursday,
June 15 at 12:30 pm CT
Location: Board no. THU-165, ENDOExpo Hall,
McCormick Place
Session title: Pediatric endocrinology:
Pediatric disorders of growth
Session number: P10
Evaluation of bone mineral density in a cohort of children
with achondroplasia participating in the PROPEL 2 study of
infigratinib
Poster presentation date & time: Thursday,
June 15 at 12:30 pm CT
Location: Board no. THU-181, ENDOExpo Hall,
McCormick Place
Session title: Pediatric endocrinology:
Pediatric disorders of growth
Session number: P10
ADH1 oral presentation, rapid fire presentation and poster details:
Sustained normalization of mineral homeostasis in autosomal
dominant hypocalcemia type 1: Results from a Phase 2 study
over 18 months of encaleret (CLTX-305) treatment
(NCT04581629)
Presenter: Rachel Gafni, M.D., senior research
physician and head of the Mineral Homeostasis Studies Group of
the National Institute of Dental and Craniofacial Research of
the National Institutes of Health (NIH)
Oral presentation date & time: Saturday,
June 17 at 4:00 pm CT
Location: W-183C, McCormick Place
Session title: PTH – Relevant biology,
pathophysiology, and therapeutics
Session number: OR23-03
Next-generation sequencing for detection of underlying
genetic causes of nonsurgical hypoparathyroidism: Preliminary
results from a sponsored testing program
Presenter: Michael Mannstadt, M.D., chief of
the Endocrine Unit at Massachusetts General Hospital and
associate professor in Medicine at Harvard Medical School
Rapid fire presentation date & time: Saturday, June 17 at 1:00 pm CT
Poster presentation date & time: Saturday,
June 17 at 1:00 pm CT
Location: Board no. SAT-231, ENDOExpo Hall,
McCormick Place
Session title: Bone and mineral metabolism:
hypoparathyroidism
Session number: P69
About BridgeBio Pharma, Inc.
BridgeBio Pharma Inc. (BridgeBio) is a commercial-stage
biopharmaceutical company founded to discover, create, test and
deliver transformative medicines to treat patients who suffer
from genetic diseases and cancers with clear genetic drivers.
BridgeBio’s pipeline of development programs ranges from early
science to advanced clinical trials. BridgeBio was founded in
2015 and its team of experienced drug discoverers, developers,
and innovators are committed to applying advances in genetic
medicine to help patients as quickly as possible. For more
information visit bridgebiodev.wpengine.com and follow us on LinkedIn and Twitter.
BridgeBio Media Contact:
Vikram Bali
[email protected]
(650)-789-8220